We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MOLECULAR IDENTIFICATION AND ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA TROPICALIS AND CANDIDA PARAPSILOSIS ISOLATED FROM CANCER PATIENTS.
- Authors
Wijendra, W. A. S.; Ganguli, S. C.; Dasanayaka, P. N.; Ramesh, R.; Kaushalya, A. G. G.; Gunasekara, S.
- Abstract
Candida species cause systemic candidiasis in immunocompromised cancer patients. Currently, a large proportion of bloodstream infections are due to non-albicans Candida species (Candida species other than C. albicans), with Candida tropicalis and Candida parapsilosis being the most isolated Candida species from cancer patients. In this study, 52 Candida isolates were collected from cancer patient at the Apeksha Hospital, Maharagama, Sri Lanka. Molecular identification of isolated Candida samples employed a multiplex PCR technique utilizing specific primer pairs for two strains of both Candida tropicalis and Candida parapsilosis. Furthermore, to determine the susceptibility of the identified isolates, antifungal susceptibility testing was conducted using the disk diffusion method on Mueller-Hinton agar medium. Six antifungal drugs, including Fluconazole, Itraconazole, Clotrimazole, Miconazole, Ketoconazole, and Amphotericin B, were utilized in the susceptibility testing. In this study 38% of the strains were identified as Candida tropicalis II while, 31% were identified as Candida parapsilosis II. According to this study Fluconazole was the most susceptible drug against both species and Amphotericin B was the least susceptible drug. Ketoconazole, Clotrimazole, Itraconazole and Miconazole showed varying degrees of susceptibility patterns. The study concludes that multiplex PCR is a better approach for the identification of both Candida tropicalis and Candida parapsilosis for clinical and diagnostic purposes and Fluconazole is the best antifungal drug against Candida parapsilosis, while caution is advised when using Amphotericin B as a treatment option since its' low susceptible rates.
- Subjects
CANDIDA tropicalis; CANCER patients; ITRACONAZOLE; AMPHOTERICIN B; CLOTRIMAZOLE; ANTIFUNGAL agents; KETOCONAZOLE
- Publication
Journal of Experimental & Molecular Biology, 2024, Vol 25, Issue 1, p59
- ISSN
2601-6974
- Publication type
Article
- DOI
10.47743/jemb-2024-108